Clinical Trials · NCT02251431
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Baylor Research Institute
- Enrollment
- 57
- Start date
- Nov 2015
- Locations
- 1 site, United States
- Primary endpoint
- Galectin-3